Interleukin-21 Inhibits HBV Replication in vitro

Lu F.M. , Zhuang H. Management of hepatitis B in China. Chin Med J (Engl) 2009; 122: 3–4.

Arama V. , Leblebicioglu H. , Simon K. Chronic hepatitis B monitoring and treatment patterns in five European countries with different access and reimbursement policies. Antivir Ther 2014; 19: 245–257.

Liaw Y.F. , Chu C.M. Hepatitis B virus infection. Lancet 2009; 373: 582–592.

Dienstag J.L. Hepatitis B virus infection. N Engl J Med 2008; 359: 1486–1500.

Shen G. , Fu X. , Zhou B. Duck HBV DNA copy numbers in isolated hepatocyte nuclei vary dramatically and decline during entecavir therapy. Antivir Ther 2013; 18: 987–996.

Thimme R. , Wieland C. , Steiger J. CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol 2003; 77: 68–76.

Murray J.M. , Wieland S.F. , Purcell R.H. Dynamics of hepatitis B virus clearance in chimpanzees. Proc Natl Acad Sci U S A 2005; 102: 17780–17785.

Guidotti L.G. , Rochford G.R. , Chung J. Viral clearance without destruction of infected cells during acute HBV infection. Science 1999; 284: 825–829.

Phillips S. , Chokshi S. , Riva A. CD8(+) T cell control of hepatitis B virus replication: direct comparison between cytolytic and noncytolytic functions. J Immunol 2010; 184: 287–295.

Lucifora J. , Xia F. , Reisinger K. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science 2014; 343: 1221–1228.

Spolski R. , Leonard W.J. Interleukin-21: basic biology and implications for cancer and autoimmunity. Annu Rev Immunol 2008; 26: 57–79.

Yi J.S. , Du M. , Zajac A.J. A vital role for interleukin-21 in the control of a chronic viral infection. Science 2009; 324: 1572–1576.

Sutherland A.P. , Joller N. , Michaud M. IL-21 promotes CD8⁺ CTL activity via the transcription factor T-bet. J Immunol 2013; 190: 3977–3984.

Hsu C.S. , Hsu S.J. , Liu W.L. IL-21R gene polymorphisms and serum IL-21 levels predict virological response to interferon-based therapy in Asian chronic hepatitis C patients. Antivir Ther 2013; 18: 599–606.

Strengell M. , Matikainen J. , Siren A. IL-21 in synergy with IL-15 or IL-18 enhances IFN-gamma production in human NK and T cells. J Immunol 2003; 170: 5464–5469.

Maeda M. , Yanagawa Y. , Iwabuchi K. IL-21 enhances dendritic cell ability to induce interferon-gamma production by natural killer T cells. Immunobiology 2007; 212: 537–547.

Publicover J. , Goodsell A. , Nishimura S. IL-21 is pivotal in determining age-dependent effectiveness of immune responses in a mouse model of human hepatitis B. J Clin Invest 2011; 121: 1154–1162.

Serti E. , Doumba P.P. , Thyphronitis G. Modulation of IL-2 expression after uptake of hepatitis C virus non-enveloped capsid-like particles: the role of p38 kinase. Cell Mol Life Sci 2011; 68: 505–522.

Wang Z. , Wu L. , Cheng X. Replication-competent infectious hepatitis B virus vectors carrying substantially sized transgenes by redesigned viral polymerase translation. PLoS ONE 2013; 8: e60306.

Sun D. , Nassal M. Stable HepG2- and Huh7-based human hepatoma cell lines for efficient regulated expression of infectious hepatitis B virus. J Hepatol 2006; 45: 636–645.

Zhang S. , Kodys K. , Li K. Human type 2 myeloid dendritic cells produce interferon-lambda and amplify interferon-alpha in response to hepatitis C virus infection. Gastroenterology 2013; 144: 414–425.

Doumba P.P. , Nikolopoulou M. , Gomatos I.P. Co-culture of primary human tumor hepatocytes from patients with hepatocellular carcinoma with autologous peripheral blood mononuclear cells: study of their in vitro immunological interactions. BMC Gastroenterol 2013; 13: 17.

Seignères B. , Pichoud C. , Martin P. Inhibitory activity of dioxolane purine analogs on wild-type and lamivudine-resistant mutants of hepadnaviruses. Hepatology 2002; 36: 710–722.

Sadler A.J. , Williams B.R. Interferon-inducible antiviral effectors. Nat Rev Immunol 2008; 8: 559–568.

Crowther C. , Mowa M.B. , Ely A. Inhibition of HBV replication in vivo using helper-dependent adenovirus vectors to deliver antiviral RNA interference expression cassettes. Antivir Ther 2014; 19: 363–373.

Guidotti L.G. , Ishikawa T. , Hobbs M.V. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 1996; 4: 25–36.

Wieland S.F. , Spangenberg H.C. , Thimme R. Expansion and contraction of the hepatitis B virus transcriptional template in infected chimpanzees. Proc Natl Acad Sci U S A 2004; 101: 2129–2134.

Feng G. , Zhang J.Y. , Zheng Q.L. Interleukin-21 mediates hepatitis B virus-associated liver cirrhosis by activating hepatic stellate cells. Hepatol Res 2014; 44: E198–E205.

Bachmann M.F. , Wolint P. , Walton S. Differential role of IL-2R signaling for CD8⁺ T cell responses in acute and chronic viral infections. Eur J Immunol 2007; 37: 1502–1512.

Brooks D.G. , Trifilo M.J. , Edelmann K.H. Interleukin-10 determines viral clearance or persistence in vivo. Nat Med 2006; 12: 1301–1309.

Ejrnaes M. , Filippi C.M. , Martinic M.M. Resolution of a chronic viral infection after interleukin-10 receptor blockade. J Exp Med 2006; 203: 2461–2472.

Cheong J.Y. , Cho S.W. , Hwang I.L. Association between chronic hepatitis B virus infection and interleukin-10, tumor necrosis factor-alpha gene promoter polymorphisms. J Gastroenterol Hepatol 2006; 21: 1163–1169.

Blackburn S.D. , Wherry E.J. IL-10, T cell exhaustion and viral persistence. Trends Microbiol 2007; 15: 143–146.

Bozkaya H. , Bozdayi M. , Turkyilmaz R. Circulating IL-2, IL-10 and TNF-alpha in chronic hepatitis B: their relations to HBeAg status and the activity of liver disease. Hepatogastroenterology 2000; 47: 1675–1679.

Poovorawan K. , Tangkijvanich P. , Chirathaworn C. Circulating cytokines and histological liver damage in chronic hepatitis B infection. Hepat Res Treat 2013; 2013: 757246.

Sprengers D. , Stoop J.N. , Binda R.S. Induction of regulatory T-cells and interleukin-10 producing cells in non-responders to pegylated interferon-alpha therapy for chronic hepatitis B. Antivir Ther 2007; 12: 1087–1096.